ANI Pharmaceuticals Reports FDA Approval And Commercialization Of Ketoconazole Shampoo, 2%
Portfolio Pulse from Benzinga Newsdesk
ANI Pharmaceuticals has received FDA approval for its generic version of Ketoconazole Shampoo, 2%, which is a generic version of Nizoral. The U.S. annual sales for this product are approximately $69.2 million.
September 26, 2024 | 10:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ANI Pharmaceuticals has received FDA approval for its generic Ketoconazole Shampoo, 2%, which could potentially capture a share of the $69.2 million market.
The FDA approval allows ANI Pharmaceuticals to commercialize its generic version of Ketoconazole Shampoo, 2%, which is a significant opportunity given the $69.2 million market size. This approval is likely to positively impact ANIP's stock price in the short term as it opens up a new revenue stream.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100